Discounted Cash Flow (DCF) Analysis Unlevered

Orphazyme A/S (ORPH)

$ 4.51
-0.06 -1.31%

Operating Data

Year
A/P
2016
Projected
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 4.51
Beta 0.640
Diluted Shares Outstanding 20
Cost of Debt
Tax Rate 0.30
After-tax Cost of Debt 4.98%
Risk-Free Rate
Market Risk Premium
Cost of Equity 7.558
Total Debt 57.18
Total Equity 90.21
Total Capital 147.39
Debt Weighting 38.79
Equity Weighting 61.21
Wacc

Build Up Free Cash

Year
A/P
2016
Projected
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 8.67%4.18%2.34%1.60%0.30%3.42%3.42%3.42%3.42%3.42%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0.24-1.49-2.35-3.29-5.10-----
UFCF ----------
WACC
PV UFCF ----------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 6.56
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -669.75
Equity Value -
Shares Outstanding 20
Equity Value Per Share -